Tekmira Pharmaceuticals has expanded its multi-year collaboration with Bristol-Myers Squibb to include newly developed Tekmira proprietary lipid nanoparticle (LNP) formulations for delivery to tumors and other tissues outside the liver. The two companies are also expanding ongoing target validation work. Under the original agreement, BMS is using small interfering RNA (siRNA) molecules formulated by Tekmira in LNPs to silence target genes of interest. BMS is conducting the preclinical work to...